France Antifungal Drugs Market Size & Outlook, 2023-2030
France antifungal drugs market, 2018-2030 (US$M)
Related Markets
France antifungal drugs market highlights
- The France antifungal drugs market generated a revenue of USD 606.0 million in 2023 and is expected to reach USD 794.7 million by 2030.
- The France market is expected to grow at a CAGR of 3.9% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 606.0 million |
| Market revenue in 2030 | USD 794.7 million |
| Growth rate | 3.9% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, France accounted for 3.8% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,215.7 million by 2030.
Azoles was the largest segment with a revenue share of 47.79% in 2023. Horizon Databook has segmented the France antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
In France, the market is expected to witness lucrative growth owing to the increasing number of collaborations between key players operating in the space for the treatment of fungal infections.
For instance, in July 2021, Almirall, S.A. and KAKEN PHARMACEUTICAL CO., LTD. signed a licensing and distribution agreement for the topical formulation of efinaconazole in France. Such strategic initiatives by market players are expected to fuel market growth in the country.
Healthcare in France is based on a Bismarck social health insurance system. Regarding reimbursement and pricing of drugs, key institutions are the National Union of Health Insurance Funds (UNCAM), the High Authority of Health (HAS), and the Ministry of Solidarity and Health.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France antifungal drugs market size, by drug class, 2018-2030 (US$M)
France Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
